| Sudden unexpected death in persons< 40 years of age Y Drory, Y Turetz, Y Hiss, B Lev, EZ Fisman, A Pines, MR Kramer The American journal of cardiology 68 (13), 1388-1392, 1991 | 681 | 1991 |
| Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome A Tenenbaum, M Motro, EZ Fisman, D Tanne, V Boyko, S Behar Archives of internal medicine 165 (10), 1154-1160, 2005 | 393 | 2005 |
| Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons A Tenenbaum, M Motro, EZ Fisman Cardiovascular diabetology 4, 1-5, 2005 | 310 | 2005 |
| Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? EZ Fisman, A Tenenbaum Cardiovascular diabetology 13, 1-10, 2014 | 273 | 2014 |
| Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor A Tenenbaum, R Klempfner, EZ Fisman Cardiovascular diabetology 13, 1-10, 2014 | 254 | 2014 |
| Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two–year follow-up of the … R Klempfner, A Erez, BZ Sagit, I Goldenberg, E Fisman, E Kopel, ... Circulation: Cardiovascular Quality and Outcomes 9 (2), 100-108, 2016 | 252 | 2016 |
| Ischemic preconditioning: nearly two decades of research. A comprehensive review A Eisen, EZ Fisman, M Rubenfire, D Freimark, R McKechnie, ... Atherosclerosis 172 (2), 201-210, 2004 | 246 | 2004 |
| The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow A Pines, EZ Fisman, Y Levo, M Averbuch, A Lidor, Y Drory, A Finkelstein, ... American journal of obstetrics and gynecology 164 (3), 806-812, 1991 | 229 | 1991 |
| Peroxisome proliferator–activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease A Tenenbaum, M Motro, EZ Fisman, E Schwammenthal, Y Adler, ... Circulation 109 (18), 2197-2202, 2004 | 225 | 2004 |
| Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction A Tenenbaum, EZ Fisman Cardiovascular diabetology 11 (1), 125, 2012 | 221 | 2012 |
| Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction EZ Fisman, M Benderly, RJ Esper, S Behar, V Boyko, Y Adler, D Tanne, ... The American journal of cardiology 98 (1), 14-18, 2006 | 180 | 2006 |
| Calcification of the thoracic aorta as detected by spiral computed tomography among stable angina pectoris patients: association with cardiovascular events and death A Eisen, A Tenenbaum, N Koren-Morag, D Tanne, J Shemesh, M Imazio, ... Circulation 118 (13), 1328-1334, 2008 | 175 | 2008 |
| Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level A Hiuge, A Tenenbaum, N Maeda, M Benderly, M Kumada, EZ Fisman, ... Arteriosclerosis, Thrombosis, and Vascular Biology 27 (3), 635-641, 2007 | 172 | 2007 |
| Myocardial ischemia during sexual activity in patients with coronary artery disease Y Drory, I Shapira, EZ Fisman, A Pines The American journal of cardiology 75 (12), 835-837, 1995 | 168 | 1995 |
| Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR) A Tenenbaum, EZ Fisman, M Motro Cardiovascular diabetology 2, 1-7, 2003 | 144 | 2003 |
| Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? A Tenenbaum, EZ Fisman Cardiovascular diabetology 11 (1), 140, 2012 | 134 | 2012 |
| Functional class in patients with heart failure is associated with the development of diabetes A Tenenbaum, M Motro, EZ Fisman, J Leor, D Freimark, V Boyko, ... The American journal of medicine 114 (4), 271-275, 2003 | 129 | 2003 |
| Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins A Tenenbaum, EZ Fisman, M Motro, Y Adler Cardiovascular diabetology 5, 1-8, 2006 | 128 | 2006 |
| The ubiquitous interleukin-6: a time for reappraisal EZ Fisman, A Tenenbaum Cardiovascular diabetology 9, 1-6, 2010 | 127 | 2010 |
| The ubiquitous interleukin-6: a time for reappraisal EZ Fisman, A Tenenbaum Cardiovascular diabetology 9, 1-6, 2010 | 127 | 2010 |
